Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.
Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.
Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.
With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.
Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.
Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.
Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.
As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ: EVO) announced that Dr Matthias Evers, Chief Business Officer, will step down effective 01 October 2024 to pursue opportunities outside the company. Evers, appointed on 01 May 2022, played a important role in establishing Evotec's biologics segment Just - Evotec Biologics and aiding the company's recovery from a cyber-attack. The Supervisory Board expressed gratitude for his contributions during challenging times.
Following Evers' departure, the responsibilities of the CBO function will be distributed across other Management Board functions. Dr Christian Wojczewski, CEO of Evotec, thanked Evers for his commitment and leadership, particularly highlighting his support during the transition period.
Evotec SE reported challenging H1 2024 results, with revenues down 7% year-on-year in Shared R&D Services. Just - Evotec Biologics showed strong growth with a 50% revenue increase. The company is implementing a priority reset for sustainable profitable growth, aiming for annualized savings of at least €40m in 2025. Key points include:
- Group revenues increased by 2% to €390.8m
- Adjusted Group EBITDA totaled €(0.5)m, impacted by high fixed costs
- New collaborations signed with various partners
- Dr Christian Wojczewski took over as CEO on July 1, 2024
- Headcount reduction of approximately 400 roles planned
- Full-year 2024 outlook: revenues expected €790-820m, adjusted EBITDA €15-35m
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ: EVO) announced significant progress in its strategic partnership with Bristol Myers Squibb focused on developing molecular glue degraders. The collaboration, initiated in 2018 and expanded in 2022, has triggered performance-based and programme-based payments totaling US$ 75 million to Evotec. This partnership combines Evotec's multi-omics screening capabilities with Bristol Myers Squibb's library of cereblon E3 ligase modulators (CELMoDs™) to identify novel molecular glue degraders for oncology and other fields.
Dr. Cord Dohrmann, Evotec's Chief Scientific Officer, highlighted the growing pipeline of molecular degraders addressing high-value targets, emphasizing the potential to deliver multiple first-in-class products to the market. The collaboration's success underscores Evotec's progress in this emerging therapeutic modality.
Evotec SE announced significant progress in its strategic neuroscience partnership with Bristol Myers Squibb, resulting in a US$ 25 million payment to Evotec for further research advancement. The collaboration, initiated in December 2016, aims to develop disease-modifying treatments for neurodegenerative diseases. Evotec's PanOmics platform, combined with patient-derived disease models, has been instrumental in generating a promising pipeline of discovery to clinical-stage programmes.
A key milestone was reached with the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. The partnership was extended for an additional 8 years in March 2023. Dr. Cord Dohrmann, Evotec's CSO, highlighted the productive nature of the collaboration and expressed excitement about advancing another programme towards clinical development in 2026.
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, NASDAQ: EVO) has announced it will release its financial results for the first half-year of 2024 on Wednesday, 14 August 2024. The company will host a conference call and webcast to discuss the results and provide a performance update. The event will be conducted in English.
Key details:
- Webcast: 14 August 2024, 2:00 pm CEST (1:00 pm BST, 8:00 am EDT)
- Conference call: Pre-registration required
- Slide presentation available for phone participants
- On-demand version will be accessible on Evotec's website
Evotec SE has updated its guidance for fiscal year 2024, reflecting challenges in the first half of the year. The company now expects:
- Revenues of €790-820 million (low to mid-single-digit percentage growth)
- R&D expenditures of €50-60 million (low double-digit percentage reduction)
- Adjusted EBITDA of €15-35 million (mid-double-digit percentage reduction)
The Shared R&D segment faced a challenging environment, while Just - Evotec Biologics saw mid-double-digit revenue growth. The company is implementing measures to reset operational priorities, focusing on sustainable profitable growth and right-sizing its business. Annualized recurring benefits on adjusted EBITDA are expected to exceed €40 million. Evotec is evaluating additional strategic steps and developing a new mid-range plan.
Evotec SE (NASDAQ: EVO) has updated its fiscal year 2024 guidance. The company now expects:
- Group revenues of €790-820 million (low to mid-single-digit percentage growth, down from previous low double-digit growth)
- R&D expenditures of €50-60 million (low double-digit percentage reduction)
- Adjusted EBITDA of €15-35 million (mid double-digit percentage reduction, down from previous mid double-digit growth)
The guidance revision is due to slower sales order conversion and continued margin pressure from high fixed costs. Evotec is implementing actions to transform the business towards sustainable profitable growth.
Evotec SE has entered into a multi-year collaboration with Pfizer to advance early discovery research for metabolic and infectious diseases. The research will be conducted at Evotec's French facilities, including Campus Curie in Toulouse. Evotec will receive research support funding from Pfizer and may earn milestones and royalties based on the program's success. This partnership aims to leverage Evotec's extensive research capabilities and Pfizer's commitment to fostering new therapeutic approaches. Both companies highlight the strong biopharmaceutical ecosystem in France as a important factor in their collaboration.
Just - Evotec Biologics, a segment of Evotec, has expanded its strategic partnership with Sandoz, focusing on the development and commercial manufacturing of biosimilars. This agreement, announced on July 8, 2024, ensures long-term commercial supply security for Sandoz from Evotec's newly built J.POD® manufacturing facility in Toulouse, France. The extended partnership promises remuneration for early scientific validation and additional funding upon reaching development milestones from 2025. Since May 2023, the collaboration has leveraged Just - Evotec Biologics' data-driven design and continuous manufacturing technology to enhance product quality and cost efficiency. Dr. Matthias Evers, Evotec's Chief Business Officer, highlighted the potential to improve patient access to medicines and validate the strategic establishment of their second J.POD® facility.
Evotec SE's subsidiary, Just - Evotec Biologics, has been selected by the U.S. Department of Defense (DOD) to develop an accelerated monoclonal antibody (
FAQ
What is the current stock price of Evotec SE American Depositary Shares (EVO)?
What is the market cap of Evotec SE American Depositary Shares (EVO)?
What is Evotec SE?
What are Evotec's main business segments?
Who are Evotec's partners?
What recent collaborations has Evotec entered into?
How many employees does Evotec have?
What are Evotec's key therapeutic areas?
What financial performance did Evotec report in 2023?
What are the future goals of Evotec?
What is Just-Evotec Biologics?
What makes Evotec's platform unique?
